{"id":"NCT01202903","sponsor":"Novartis Pharmaceuticals","briefTitle":"Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy","officialTitle":"A 24-week, Phase III Randomized, Double-blind, Placebocontrolled, Parallel-group, Multicenter Study of XolairÂ® (Omalizumab) in Patients With Moderate to Severe Persistent Allergic Asthma Who Remain Not Adequately Controlled Despite GINA (2009) Step 4 Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-09","primaryCompletion":"2013-10","completion":"2013-10","firstPosted":"2010-09-16","resultsPosted":"2015-03-23","lastUpdate":"2015-03-23"},"enrollment":616,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Persistent Allergic Asthma"],"interventions":[{"type":"DRUG","name":"Omalizumab","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Omalizumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will assess the efficacy, safety and tolerability of omalizumab, compared to placebo in 18 to 75 year old Chinese patients with moderate to severe persistent allergic asthma who have inadequate asthma control despite treatment according to GINA (2009) Step 4 therapy.","primaryOutcome":{"measure":"Change From Baseline in Mean Morning Peak Expiratory Flow (PEF) Following the 24-week Treatment Period","timeFrame":"Baseline, 24 weeks","effectByArm":[{"arm":"Omalizumab","deltaMin":27.03,"sd":20.865},{"arm":"Placebo","deltaMin":18.18,"sd":21.086}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":8},"locations":{"siteCount":39,"countries":["China"]},"refs":{"pmids":["34611470"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":310},"commonTop":["Upper respiratory tract infection","Asthma","Nasopharyngitis","Rhinitis allergic","Influenza"]}}